8-K filed Jul 29, 2026 at 07:01 ET
IDEX reported Q2 2026 adjusted EPS of $2.32, a 10% beat vs consensus of $2.11, on record sales of $921M (+6% reported, +5% organic). Full-year organic growth guidance was raised to 5-6% (from 3-4%) and adjusted EPS guidance to $8.70-$8.85 (from $8.35-$8.55), representing ~10% YoY growth at midpoint. Record orders of $1.07B (+29%) underscore exceptional momentum in the Health Science Technologies segment driven by AI/semiconductor and aerospace/defense demand. This marks a second consecutive beat-and-raise quarter.